| Name | N-(4-Chloro-2-fluorophenyl)-2-hydroxybenzamide |
|---|---|
| Synonyms |
Benzamide, N-(4-chloro-2-fluorophenyl)-2-hydroxy-
MFCD13200880 N-(4-Chloro-2-fluorophenyl)-2-hydroxybenzamide |
| Description | NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene express. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al[1]. |
|---|---|
| Related Catalog | |
| In Vitro | NDMC101 (10-15 µM) inhibits RANKL-induced osteoclast differentiation of bone marrow-derived macrophages (BMDMs) and RAW 264.7 cells[1]. NDMC101 (15 µM) decreases RANKL-induced expression of the osteoclastogenic genes Nfatc1, Acp5, Ctsk, Oscar, Itgb3, and Dcstamp in BMDMs[1]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 311.1±42.0 °C at 760 mmHg |
| Molecular Formula | C13H9ClFNO2 |
| Molecular Weight | 265.668 |
| Flash Point | 142.0±27.9 °C |
| Exact Mass | 265.030579 |
| LogP | 3.58 |
| Vapour Pressure | 0.0±0.7 mmHg at 25°C |
| Index of Refraction | 1.661 |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| RIDADR | NONH for all modes of transport |